IPT-weighted cumulative incidence and SHRs in the intention-to-treat analysis for factor Xa inhibitor cohort versus the dabigatran cohort during 5 years of follow-up.
Advances in antiretroviral therapies (ART) and patient management have improved survival of people living with HIV (PLWH). However, with exposure to ART and associated side effects and toxicities as w
